Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I voted "for" across the board after the release of the phase 1 results. GLTA
Last years third quarter 10-Q was filed on 11/14/2013. So IMO we can expect this years 10-Q early November as well. IMO it will be a catalyst for the stock as I assume they will report breaking more than 1 mil in revenues for the year. Exciting times as the companies growth continues to pick up pace.
I was just wondering the same thing and came on here to ask if anyone knew?? I would assume so
Continued increased revenues to be reported by BHRT soon!! IMO
BioHeart posted this link on its Twitter page yesterday about MyoCell ;)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668534/
You got me.... NOT!! IMO.
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH
Sunrise, Fla – August 7, 2014 – Bioheart, Inc. (BHRT.OB) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart product revenues are up from $24,321 to $819,606 comparing YTD 2013 to YTD 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. Bioheart’s YTD net income increased to $226,034, as compared to a net loss of $1,269,231 in YTD 2013, primarily resulting from gain on settlement of debt.
“The financial backbone of Bioheart is getting stronger and we continue to make strides on a daily basis,” said Mike Tomas, Bioheart's president and CEO. “We have experienced two very strong quarters this year and will try to continue to improve
the well-being of Bioheart for our shareholders.”
Bioheart has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in YTD 2013 down to $507,000 in YTD 2014. Bioheart has been focused on reducing debt and decreasing current liabilities by $3.6 million (27%) from the beginning of the year. In addition, Bioheart has made strides to improve its working capital deficiency, decreasing the deficit by 28% from the beginning of the year.
How do you not see the massive potential in this stock?? IMO
Thanks Gs. They mentioned they recently opened up a new office together in sunrise Florida
Can you post the link Gs please?
I think it's due to all the current world events taking place.
Awesome update. Full results not yet out.
Excellent video chuck.
It begins... Seems as if the patience is finally going to pay off.
http://www.npr.org/blogs/health/2014/10/14/346174070/embryonic-stem-cells-restore-vision-in-preliminary-human-test
http://m.sfgate.com/news/article/Stem-cells-to-treat-blindness-appear-to-be-safe-5822529.php
IMO we recover tomorrow. GLTA.
Excellent choice. I too won't decide yet. I'm going to wait on the next 2 weeks of trade and material events... Then decide.
Hmm... Interesting. I've always found that my initial decision is the correct one and when I have a change of heart toward a decision I end up making the wrong one. IMO always stick to your gut feeling... Ones first opinion.
Your posts convince me to buy more shares.
I received the proxy today via e-mail (scottrade)
An Overview of Adipose-Derived Mesenchymal
Stem Cells (MSCs) for Orthopedic Conditions
Date: Thursday October 9, 2014
Time: 4:00 PM - 5:00 PM PDT
(7:00 PM - 8:00 PM EDT)
Presenter: Dr. Laurence McClish
Laurence McClish MD
is a board-certified orthopedic
surgeon and long-standing member of the American Academy of Orthopedic Surgeons (AAOS). Dr. McClish completed a Masters Degree in Metabolic and Nutritional Medicine through the University of South Florida Medical School, and received advanced fellowship training in Anti-Aging, Regenerative and Functional Medicine from A4M.
Present in a Best Practices Webinar!
A peer discussion on the best practices for stem cell therapy!
Conditions you are treating with stem cells
Adipose/bone marrow extraction techniques
Results you are experiencing with stem cells
Educating patients on stem cells & banking
Contact Us Today!
BIOHEART, INC.
13794 NW 4th Street, Suite 212, Sunrise, Florida
Phone: 954.835.1500 | Fax: 954.845.9976 | cmatton@bioheartinc.com
Forward this email
STAY CONNECTED
Like us on Facebook Follow us on Twitter View our profile on LinkedIn View our videos on YouTube
Forward this email
This email was sent to
*********
bioheart@bioheartinc.com |
Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.
Bioheart, Inc. | 13794 NW 4th Street | Suite 212 | Sunrise | FL | 33325
What are you talking about?? Each sale is complimented by a purchase... It's a price haggle, that's all.
If I chose to sell today at the current price is still profit. Some have profited and are happy and sold while others are looking to buy in and profit from the future growth. It is not rocket science. I choose to HOLD because IMO there is much more profit to be made considering the substantial increase in REVENUES, PARTNERSHIPS and TRIALS the company has recently achieved and is IMO on track to continue to achieve. A little DD will tell the same story I've just relayed IMO.
I strongly agree. Debt reduction and significant increases of revenue is what is taking place currently. Next stop:
Phase 1 Adipocell results
Phase 3 Myocell enrollment completion
IMO.
Yeah BDO is big... Sometimes when I watch Bloomberg television, BDO commercials air.
I agree. Shareholders are doing just that, holding. IMO we know what's coming and will wait till the to sell.
What's your short interest??
Absolutely not.
REMEMBER, before the year is over as stated by ACTCD leaders we will:
Release TLD in NEJM
Up list to Nasdaq
And begin phase 2
All major catalysts that will IMO propel the pps
Yes I agree, he's trying to create these stops with his glorified blog that interpret as pathetic.
How do we know this patient has actually had cataract surgery? Or are we just trusting the yellow journalists word?
Seeking alpha is absolute garbage. I've said it before.
Why would ACTC apply to have phase 1 results published in NEJM if the results were not NEJM worthy... Ever since our last run up with the new 52 week high we've been attacked beginning with the sec article...
I believe ACTC has an absolute dominant position in the field and is leading the way ON ITS OWN. We don't know of what they have turned down or who they've turned down and as a result what big power players such as big Pharma have marked ACTC as a target.
When those phase 1 results are released and ACTC finally gets the type of journalism it deserves... I'll still be long ACTC because the journey is just getting started. IMO glta
When does that "D" get dropped off again??
Good day. Look forward to more tomorrow IMO. GLTA
Awesome read about bone marrow stem cells injected via catheter into the heart for post heart attack patients. University of Miami par takes in this trial.
http://www.nytimes.com/2014/09/16/science/stem-cell-progress-begins-to-catch-up-to-promise.html?hp&action=click&pgtype=Homepage&version=HpSumSmallMediaHigh&module=second-column-region®ion=top-news&WT.nav=top-news&_r=2
Can't move forward in the past 4 years?!? We've enrolled the first patient in our phase 3 just last year!!
BIOHEART ANNOUNCES PHASE III MIRROR TRIAL FOR MYOCELL INITIATED
_______________________________________________________
Sunrise, FL – July 2nd, 2013 - Bioheart, Inc. (BHRT.OB) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell® or muscle derived stem cells.
The MIRROR trial is fully funded by Bioheart and will be conducted at up to 35 centers in North and South America. The trial is designed to enroll up to 126 patients over a 12 month time period. The first patient has been enrolled in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This study will complement the data completed in the Phase II/III MARVEL trial on patients with congestive heart failure (CHF). Patients are randomized into either the treatment (2/3) or placebo (1/3) arm. All patients will receive delivery into the damaged areas of the heart using the MyoCath® Catheter. Data endpoints will include safety, exercise capacity, quality of life, and ejection fraction at 3 months and 6 months. Kristin Comella, Bioheart’s Chief Science Officer said “We are hoping to achieve results similar to those from the MARVEL trial in which patients improved almost 100 meters over placebo in their exercise capacity test. We believe this therapy can address an unmet need for cardiac patients.”
The FDA has placed a hold on the request for an Expanded Access protocol using MyoCell in part because the proposed expanded access study would likely interfere with the clinical development of MyoCell and/or interfere with developing market approval. Bioheart intends to continue enrollment in the MIRROR trial while hold items are addressed with the FDA. In addition, Bioheart plans to initiate part 2 of the MARVEL trial using the J&J MyoStarTM Catheter to deliver MyoCell to CHF patients.
From the last 10Q
"We have completed the Phase 1 Angel Trial for AdipoCell (adipose derived stem cells). Five patients were enrolled and treated in the second quarter of 2013.
We have also initiated several Institutional Review Board studies in 2013 using adipose derived stem cells for various indications including dry macular degeneration, degenerative disc disease, erectile dysfunction and chronic obstructive pulmonary disease."
Lol you definitely were.
I don't need to type 1million words to tell you this.
BioHearts revenues for this year will far exceed 1million and possibly exceed 2 million. We now have strategic partnerships in place that will continue to generate revenues while BioHeart seeks out to continue its partnership growth. The icing on the cake will be when Adipocell phase 1 results are released and or phase 3 Myocell update occurs. IMO